迪卡斯股票討論區

$迪卡斯(DCTH.US)$ Delcath Systems Q1 2024 GAAP EPS $(0.45) Beats $(0.47) Estimate, Sales $3.139M Beat $2.187M Estimate

$迪卡斯(DCTH.US)$ Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT
1 MINUTE AGO, 9:00 AM EDT
VIA PR NEWSWIRE
Significantly Higher Overall Response Rate vs Meta-analysis of Historical Controls (36.3% vs. 5.5%)
Other Efficacy Endpoints Include a 73.6% Disease Control Rate with a 7.7% Complete Response Rate

$Annovis Bio(ANVS.US)$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US)$ 14% Clinical programs update
$Jaguar Health(JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US)$ 4% Ph1/2 positive data
$迪卡斯(DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US)$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US)$ 0...

$迪卡斯(DCTH.US)$ Delcath Systems Announces $7M Private Placement

$迪卡斯(DCTH.US)$ J-codes are reimbursement codes used by commercial insurance plans, Medicare, Medicare Advantage, and other government payers for Medicare Part B drugs like Jelmyto that are administered by a physician. Claims submission and payment are standardized with a J-code, facilitating and streamlining billing and reimbursement.

$迪卡斯(DCTH.US)$Moomoo 24/7· just1min
Delcath Systems Receives Permanent J-Code For HEPZATO

$迪卡斯(DCTH.US)$Moomoo 24/7· 1 min ago
Delcath Systems Launches Commercial Treatment Utilizing HEPZATO KIT For Treatment Of Metastatic Uveal Melanoma

$迪卡斯(DCTH.US)$ up?

$迪卡斯(DCTH.US)$ Officer MICHEL GERARD J purchased 34,000 shares of Common Stocks on Dec 8, 2023 at an average price of $2.94 for a total value of $99,960.